AstraZeneca: Perioperative Imfinzi Plus Neoadjuvant Enfortumab Vedotin Granted Priority Review in the US for Patients With Muscle-invasive Bladder Cancer
September 26, 2026
September 26, 2026
WILMINGTON, Delaware, Sept. 26 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Perioperative IMFINZI(R) (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
25 September 2026
Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overal . . .
* * *
Perioperative IMFINZI(R) (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
25 September 2026
Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overal . . .